nach oben

Erschienen in:

2011 | OriginalPaper | Buchkapitel

12. Antiinfektiva

verfasst von : Prof. Dr. Jost Leemhuis

Erschienen in: Pharmakotherapie in der Anästhesie und Intensivmedizin

Verlag: Springer Berlin Heidelberg

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Behandlung einer Infektion ist eine Hauptursache für die Aufnahme auf eine Intensivstation. Deren konsequente Behandlung hat eine erhebliche Bedeutung für das Überleben der Patienten und stellt, aufgrund der Verlängerung der Verweildauer, einen beachtlichen Kostenfaktor dar.

[1]

Agwuh KN, MacGowan A (2006) Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcydines. J Antimicrob Chemother 58:256–265PubMedCrossRef

[2]

Aider J (2008) The use of daptomycin for Staphylococcus aureus infections in critical care medicine. Crit Care Clin 24:349–352CrossRef

[3]

Baldwin CM, Lyseng-Williamson KA, Keam SJ (2008) Meropenem: A Review of its Use in the Treatment of Serious Bacterial Infections. Drugs 68:

[4]

Baughman RP (2009) The Use of Carbapenems in the Treatment of Serious Infections. J Intensive Care Med 24:230–241PubMedCrossRef

[5]

Boguniewicz M# Leung DY (1995) Hypersensitivity reactions to antibiotics commonly used in children. Pediatr Infect Dis J 14: 221–231PubMedCrossRef

[6]

Bolon MK (2009) The newer fluoroquinolones. Infect Dis Clin North Am 23:1027–1051PubMedCrossRef

[7]

Cha R, Sobel JD (2004) Fluconazole for the treatment of candidiasis: 15 years experience. Expert Rev Anti Infect Ther 2:357–366PubMedCrossRef

[8]

Clark NM, Patterson J, Joseph P, III (2003) Antimicrobial resistance among gram-negative organisms in the intensive care unit. [Miscellaneous]. Current Opinion in Critical Care 9:413–423PubMedCrossRef

[9]

Drawz SM, Bonomo RA (2010) Three Decades of {beta}-Lactama-se Inhibitors. Clin Microbiol Rev 23:160–201PubMedCrossRef

[10]

Falagas ME, Kastoris AC, Kapaskelis AM, Karageorgopoulos DE (2010) Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enter-obacteriaceae infections: a systematic review. Lancet Infect Dis 10:43–50PubMedCrossRef

[11]

Forrest GN, Tamura K (2010) Rifampin Combination Therapy for Nonmycobacterial Infections. Clin Microbiol Rev 23:14–34PubMedCrossRef

[12]

Fromm LA, Graham DL (1999) Oxacillin-induced tissue necrosis. Ann Pharmacother 33:1060–1062PubMedCrossRef

[13]

Garey KW, Salazar M, Shah D, Rodrigue R, DuPont HL (2008) Rifamycin Antibiotics for Treatment of Clostridium difficile-Associated Diarrhea. Ann Pharmacother 42:827–835PubMedCrossRef

[14]

Guay D (2007) Update on clindamycin in the management of bacterial, fungal and protozoal infections. Expert Opin Pharmacother 8:2401–2444PubMedCrossRef

[15]

Gums JG, Boatwright DW, Camblin M, Halstead DC, Jones ME, Sanderson R (2008) Differences Between Ceftriaxone and Cefotaxime: Microbiological Inconsistencies. Ann Pharmacother 42: 71–79PubMedCrossRef

[16]

Howden B, Grayson M (2006) Antimicrobial Resistance: Dumb and Dumber. The Potential Waste of a Useful Antistaphylococcal Agent: Emerging Fusidic Acid Resistance in Staphylococcus aureus. Clinical Infectious Diseases 42:394–400PubMedCrossRef

[17]

Jain R, Danziger LH (2004) The macrolide antibiotics: a pharmacokinetic and pharmacodynamic overview. Curr Pharm Des 10: 3045–3053PubMedCrossRef

[18]

Johnson DM, Biedenbach DJ, Jones RN (2002) Potency and antimicrobial spectrum update for piperacillin/tazobactam (2000): emphasis on its activity against resistant organism populations and generally untested species causing community-acquired respiratory tract infections. Diagn Microbiol Infect Dis 43:49–60PubMedCrossRef

[19]

Lichtenstern C, Nguyen TH, Schemmer P, Hoppe-Tichy T, Weigand MA (2008) Efficacy of caspofungin in invasive candidiasis and candidemia—de-escalation strategy. Mycoses 51: S35-S46CrossRef

[20]

Loo VG, Poirier L, Miller MA et al. (2005) A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N EngI J Med 353: 2442–2449CrossRef

[21]

MazzeiT, Novelli A (2009) Pharmacological properties of anti-fungal drugs with a focus on anidulafungin. Drugs 69: S79–S90CrossRef

[22]

Michalopoulos A, Falagas ME (2008) Colistin and polymyxin B in critical care. Crit Care Clin 24:377–391PubMedCrossRef

[23]

Moise PA, North D, Steenbergen JN, Sakoulas G (2009) Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptions. Lancet Infect Dis 9: 617–624PubMedCrossRef

[24]

Musher D, Logan N, Bressler A, Johnson D, Rossignol J (2009) Nitazoxanide versus Vancomycin in Clostridium difficile Infection: A Randomized, Double Blind Study. Clinical Infectious Diseases 48: e41–e46PubMedCrossRef

[25]

Nailor MD, Sobel JD (2009) Antibiotics for gram-positive bacterial infections: vancomycin, teicoplanin, quinupristin/dalfopristin, oxazolidinones, daptomycin, dalbavancin, and telavancin. Infect Dis Clin North Am 23:965–982PubMedCrossRef

[26]

Nicolau DP (2009) Management of complicated infections in the era of antimicrobial resistance: the role of tigecycline. Expert Opinion on Pharmacotherapy 10:1213–1222PubMedCrossRef

[27]

Peterson LR (2005) Antimicrobial activity and pharmacokinetics/ pharmacodynamics of the novel glycylcycline, tigecycline. Diagn Microbiol Infect Dis 52:163–164PubMedCrossRef

[28]

Rea RS, Capitano B (2007) Optimizing Use of Aminoglycosides in the Critically III. Semin Respir Crit Care Med 28:596–603PubMedCrossRef

[29]

Roberts JABP, Lipman JF (2009) Pharmacokinetic issues for antibiotics in the critically ill patient. [Article]. Critical Care Medicine 37: 840–851PubMedCrossRef

[30]

Ruhe J+, Monson T, Bradsher R, Menon A (2005) Use of Long acting Tetracyclines for Methicillin Resistant Staphylococcus aureus Infections: Case Series and Review of the Literature. Clinical Infectious Diseases 40:1429–1434PubMedCrossRef

[31]

Saner F, Gensicke J, Rath P et al. (2006) Safety profile of concomitant use of caspofungin and cyclosporine or tacrolimus in liver transplant patients. Infection 34:328–332PubMedCrossRef

[32]

Schaad UB, Suter S, Gianella-Borradori A et al. (1990) A comparison of ceftriaxone and cefuroxime for the treatment of bacterial meningitis in children. N EngI J Med 322:141–147CrossRef

[33]

Sensakovic JW# Smith LG (1995) Beta-Iactamase inhibitor combinations. Med Clin North Am 79:695–704PubMed

[34]

Stalker DJ, Jungbluth GL (2003) Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin Pharmacokinet 42:1129–1140PubMedCrossRef

[35]

Svetitsky S, Leibovici L, Paul M (2009) Comparative Efficacy and Safety of Vancomycin versus Teicoplanin: Systematic Review and Meta-Analysis. Antimicrob Agents Chemother 53: 4069–4079PubMedCrossRef

Titel: Antiinfektiva
verfasst von: Prof. Dr. Jost Leemhuis
Verlag: Springer Berlin Heidelberg
Buch: Pharmakotherapie in der Anästhesie und Intensivmedizin
Print ISBN: 978-3-540-79155-3

Electronic ISBN: 978-3-540-79156-0

Copyright-Jahr: 2011
DOI: https://doi.org/10.1007/978-3-540-79156-0_12

Neu im Fachgebiet AINS

23.04.2024 | Appendizitis | Nachrichten

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

hier abonnieren

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

12. Antiinfektiva

Zusammenfassung

Neu im Fachgebiet AINS

Hinter dieser Appendizitis steckte ein Erreger

Ärztliche Empathie hilft gegen Rückenschmerzen

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Update AINS

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Neu im Fachgebiet AINS

Hinter dieser Appendizitis steckte ein Erreger

Ärztliche Empathie hilft gegen Rückenschmerzen

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Update AINS